You are here

New Guidelines for Long-Term Management of Restless Legs Syndrome

Dopamine-receptor agonists and calcium-channel ligands recommended as first-line treatment (July 22)

The International Restless Legs Syndrome Study Group has published a report on the long-term management of restless legs syndrome (RLS) — also known as Willis-Ekbom disease (WED) — using evidence-based guidelines and clinical consensus. The report discusses consensus-based strategies for the prevention and treatment of complications, such as augmentation, loss of efficacy, excessive daytime sleepiness, and impulse control disorders, that may develop during long-term pharmacologic treatment of RLS/WED.

The new recommendations are featured in the current issue of Sleep Medicine.

One major finding of the report is recommended expansion of first-line treatment of RLS/WED for most patients. The use of either a dopamine-receptor agonist or an alpha 2 delta calcium-channel ligand is recommended as first-line treatment.

Other key statements include:

  • Pramipexole, rotigotine, and ropinirole are effective for the treatment of RLS/WED for up to 6 months.
  • Pregabalin is effective for the treatment of RLS/WED for 1 year.
  • Gabapentin enacarbil is probably effective for the treatment of RLS/WED for 1 year. Evidence is insufficient to make a recommendation on the use of this drug in the long-term treatment of RLS/WED.
  • Levodopa is probably effective for up to 2 years for the treatment of RLS/WED in the 24% to 40% of patients who tolerate therapy and who do not develop augmentation or loss of efficacy.
  • Pergolide and cabergoline should no longer be used in the treatment of RLS/WED, except for patients whose symptoms are refractory to all other treatments and in whom the benefits outweigh the risks.
  • Evidence is insufficient to make a recommendation on the use of tramadol, methadone, intrathecal morphine, or any single opioid in the long-term treatment of RLS/WED.

Sources: Reuters; July 22, 2013; and Sleep Medicine; July 2013.

More Headlines

Liver Fluke Infestation Affects Almost 2.5 Million People Globally
Policy Could Be Life-Changing for People With Spinal Cord Injury
Test Determines Severity of Pain, Helps Physicians Select Best Options
Intratumoral Injection Stimulates Immune Activation
Diabetes and Cancer Patients Could Soon Avoid Injections
Early Cancer Development May Begin in Just 30 Minutes
In Most Cases, Plaque/Tangle Dissolution Occurred Almost Instantly